GATC Biotech, service provider of DNA sequencing and bioinformatics for industry and academic research has purchased Illumina’s new HiSeq 2000 sequencing platform. This latest acquisition will further strengthen GATC Biotech’s current fleet of three GA IIx.

The company said that the instrument will initially be used for human genome sequencing projects from customers in pharmaceutical and medical research. The HiSeq 2000 sequencing system had been launched by Illumina on the occasion of the JP Morgan Healthcare Conference in San Diego.

Initially, the company is expected to employ the HiSeq 2000 to human genome sequencing projects from its customers in the pharmaceutical and medical research field. It is also expected to make the system’s high data output available to the industrial and academic research community interested in the high throughput sequencing of larger eukaryotic genomes.

Peter Pohl, CEO of GATC Biotech, said: “Illumina’s HiSeq 2000 with the estimated output of 200 GB per run allows us to virtually sequence 60 human genomes at 1x coverage in a week. Being an Illumina CSPro certified service provider we are confident to have the system quickly installed and geared up for production.”